When was Gilead founded?

Gilead was founded in 1987 and raised its 1st funding round 23 years after it was founded.

Where is Gilead located?

Gilead is headquartered in Foster City, United States.

How many employees does Gilead have?

As of Sep 30, 2026, the latest employee count at Gilead is 14855.

Is Gilead a funded company?

Gilead is a funded company, having raised an undisclosed amount across 5 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Jul 2010.

How much is Gilead worth?

The last known valuation of Gilead was $***** as of Sep 12, 2020.

When was the latest funding round of Gilead?

Gilead's latest funding was a $***** Post IPO round on Jan 27, 2025, with participation from 6 investors.

What is the annual revenue of Gilead?

Annual revenue of Gilead is more than $1B as on Dec 31, 2025

Where does Gilead rank among its competitors?

Gilead ranks 2nd amongst 1839 active competitors, of which 94 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was AstraZeneca, which secured $6.05M in Jul, 2025.

Who are the top competitors of Gilead?

Gilead's top competitors include AbbVie, Amgen and AstraZeneca. Among them, AstraZeneca secured the most recent funding round in July, 2025.

Gilead - 2026 Company Profile, Team, Funding, Competitors & Financials

Gilead is an acquired company based in Foster City (United States), founded in 1987 by Michael L Riordan. It operates as a Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others. Gilead has raised an undisclosed amount in funding, with last known valuation of $*****. The company has 1839 active competitors, including 94 funded and 204 that have exited. Its top competitors include companies like AbbVie, Amgen and AstraZeneca.

Company Details

Gilead is a developer of medicines to treat HIV/AIDS, liver diseases, cancer & others. It is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. It has developed many medicines such as Lenacapavir capsid inhibitor (GS-6207) for HIV, Long-acting treatment: 2 bNAbs (GS-5423, GS-2872), Selgantolimod TLR-8 agonist (GS-9688), PD-L1 inhibitor (GS-4224) HBV cure, and many more. In 2022, the company recorded annual revenues of $27.28B and a net profit of $4.59B.

Website: www.gilead.com/
Social
Email ID: *****@gilead.com
Phone Number: +1 **********

Key Metrics

Founded Year

1987

Location

Foster City, United States

Stage

Acquired

Latest Funding Round

Post IPO, Jan 27, 2025, $*****

Last Known Valuation

$***** as on Sep 12, 2020

Investors

BB Biotech & 18 more

Ranked

2^nd among 1839 active competitors

Annual Revenue

$1B+ as on Dec 31, 2025

Employee Count

14,855 as on Sep 30, 2026

Investment & Acquisitions

Tubulis Technologies & 48 more

Similar Companies

AbbVie & 1867 more

Exit Details

Acquired by AE Wealth Management (Apr 19, 2026)

View Gilead's full profile

Gilead is associated with 7 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Guilard, s.r.o. CIN: 29149495 , Czech Republic, Active	Jan 08, 2013	-	-
GALAAD s.r.o. CIN: 27332306 , Czech Republic, Active	Aug 16, 2007	-	-
KITES GROUP s.r.o. CIN: 05555566 , Czech Republic, Active	Nov 10, 2016	-	-
Gilead Sciences Inc CIN: 882095 , United States, Active	Jun 21, 1987	$1B+ (As on Dec 31, 2025)	-	-
Gilead Sciences, Inc. CIN: 943047598 , United States, Active	Dec 31, 2008	-	10903 (As on Dec 31, 2024)	-
GILEAD SCIENCES INDIA PRIVATE LIMITED CIN: U74120DL2014FTC308398 , India, Active	Jul 26, 2014	₹10 - ₹50 Cr (As on Mar 31, 2025)	-
Gilead Sciences, Inc. CIN: 943047598 , United States, Active	Jun 22, 1987	-	11304 (As on Dec 31, 2023)	-

Gilead got acquired by AE Wealth Management on Apr 19, 2026.

Click here to take a look at Gilead's acquisition in detail

Gilead has raised funding over 5 rounds. Its first funding round was on Jul 2010. Its latest funding round was a Post IPO round on Jan 27, 2025 for $*****. 6 investors participated in its latest round. Gilead has 19 institutional investors.

Here is the list of recent funding rounds of Gilead:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 27, 2025	2726034	Post IPO	5189692	4505057	8537375	3795719
Jul 28, 2020	6874263	Grant (prize money)	3434258	3041894	5844112	Europa
Jan 01, 2020	8144100	Grant (prize money)	6701981	5997116	3145615	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Gilead's funding rounds and investors

The founders of Gilead is Michael L Riordan. Daniel O Day is the CEO of Gilead.

Here are the details of Gilead's key team members:

Michael L Riordan: Former Founder of Gilead.
Contact Info: 1 email address
Daniel O Day: CEO of Gilead.
Contact Info: 1 email address

Gilead's Board of Directors

Gilead's board has 3 active members. Janet Elizabeth Dorling, Hans York-julian Stucker and Rahul Shivram Bargaje are independent board members.

Here is the list of Gilead's board of directors:

Name	Type	Representing	Status	Duration
Janet Elizabeth Dorling	Independent board member	-	Current	2y 11m
xwbofcm	Independent board member	-	Current	3y 8m
yvxxwx{	Independent board member	-	Current	2y 4m

View details of Gilead's Founder profiles and Board Members

Gilead's employee count trend

Gilead has 14,855 employees as of Sep 26. Here is Gilead's employee count trend over the years:

Uncover Gilead's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Gilead include AbbVie, Amgen and AstraZeneca. Here is the list of Top 10 competitors of Gilead, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Berkshire Hathaway, Alcor Fund & 9 others	83/100
2nd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	BB Biotech, Jindal ventures & 17 others	82/100
3rd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	79/100
4th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	76/100
5th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	75/100
6th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Western Technology Investment, Alcor Fund ... & 16 others	74/100
7th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 8 others	72/100
8th	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	71/100
9th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, SoftBank Group & 11 others	70/100
10th	Genentech 1976, San Francisco (United States), Acquired	R&D company focused on manufacturing drugs for multiple therapeutic areas	$72.5M	Ignite 500, The Column Group & 4 others	68/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Gilead's competitors? Click here to see the top ones

Gilead has made 29 investments in companies including Assembly Biosciences and Assembly Biosciences. Gilead has also acquired 20 companies including Tubulis Technologies and Ouro Medicines.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Apr 07, 2026	Acquisition	Tubulis Technologies	2015	Munich (Germany)
Mar 23, 2026	Acquisition	Ouro Medicines	2024	San Francisco (United States)
Feb 23, 2026	Acquisition	Arcellx	2014	Rockville (United States)